#Obesity medicine

Chronic weight management as a clinical specialty.

A non-randomized Japanese cohort reported similar six-month weight loss with 2.5 mg and 5 mg tirzepatide, without proving dose equivalence.

A mouse study tested sulforaphene-loaded α-lactalbumin nanomicelles against semaglutide, but it provides no human efficacy or safety evidence.

Australian sales and PBS data show rapid GLP-1 medicine growth, with nearly half of estimated use accessed privately in the final study year.

A SURMOUNT-OSA post hoc analysis found larger reported symptom gains from tirzepatide among people with worse symptoms at baseline.

A UK model compared sleeve gastroplasty, sleeve gastrectomy and a gastric balloon with semaglutide over five years.

A preclinical rat study tested a thermosensitive semaglutide hydrogel. It cannot establish human efficacy, dosing, or safety.

An indirect comparison favoured semaglutide on one MASH endpoint but cannot replace a randomized head-to-head trial.

A Lancet letter raises the maintenance question. SURMOUNT-MAINTAIN supports continued tirzepatide but does not supply an individual dosing formula.

A 25-year semaglutide model weighed cost per QALY against projected equity for older adults with obesity and cardiovascular disease.

A preclinical mouse study found more fat loss with vutiglabridin plus semaglutide, but it provides no evidence of human efficacy.

A Phase III trial found HD1916 met its prespecified equivalence criterion against reference semaglutide for weight change at 44 weeks.

A 2026 review asks why GIP receptor agonists and blockers can both support weight loss, then separates mouse mechanisms from human trial evidence.